SecBot SecBot
8-K ·Filed Apr 2, 2026

TCRX

TScan Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001193125-26-138973
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any subsequent filings that may indicate further executive changes or financial reporting delays, though the internal promotion of the CFO to principal accounting officer suggests operational continuity.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.01
T+0 close · Apr 2, 2026 · via day close
Latest settled
−2.96%
T+60 · $0.9801
Vs SPY
−17.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $1.01entry
  2. T+1 · 8mo ago +2.97%α +2.49% · $1.04
  3. T+5 · 7mo ago +3.96%α +0.34% · $1.05
  4. T+20 · 7mo ago +14.85%α +4.97% · $1.16
  5. T+60 · 5mo ago −2.96%α −17.12% · $0.9801
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics announced the resignation of Leiden Dworak as Vice President of Finance and principal accounting officer, effective April 10, 2026. Jason A. Amello, the company's CFO, has been appointed as the new principal accounting officer without additional compensation.

Key Facts

  • Leiden Dworak resigned as Vice President of Finance and principal accounting officer effective April 10, 2026.
  • Jason A. Amello, current CFO and principal financial officer, was appointed as principal accounting officer effective April 10, 2026.
  • No disagreements were reported between the company and Mr. Dworak regarding operations, policies, or practices.
  • Mr. Amello will not receive additional compensation for taking on the expanded role.

Financial Impact

No immediate financial impact; no change in compensation or organizational costs.

compensationorganizational structure

Risk Factors

  • Potential transitional risk in financial oversight during the role transfer, though mitigated by Amello's existing CFO position.
  • Limited insight into Dworak's reasons for departure beyond 'resignation,' though no reported disagreements reduce immediate concern.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-138973
Document: 0001193125-26-138973-index-headers.html0001193125-26-138973
Document: 0001193125-26-138973-index.html0001193125-26-138973
Document: 0001193125-26-138973.txt0001193125-26-138973

Track record

15 reports on TCRX

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026